Drugs / DDO-3055
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04775615 | Mar → May 2021 | anemia | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04470063 | Nov 2020 → Dec 2021 | anemia due to chronic disorder | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04197778 | Jan 2020 | anemia due to chronic disorder | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03976115 | Jul 2019 → May 2021 | chronic kidney disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DDO-3055 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04775615 ↗ |
| Modality | Small molecule | — CHEMBL4162752 ↗ |
| Route | Oral | “Oral” NCT03976115 ↗ |